{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:36:26Z","timestamp":1791293786519,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z201100005520013"],"award-info":[{"award-number":["Z201100005520013"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970708"],"award-info":[{"award-number":["81970708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2016YFC1305603"],"award-info":[{"award-number":["2016YFC1305603"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Nova Program of Science and Technology","award":["Z191100001119026"],"award-info":[{"award-number":["Z191100001119026"]}]},{"name":"Beijing Nova Cross program","award":["Z211100002121169"],"award-info":[{"award-number":["Z211100002121169"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00125-022-05748-9","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T05:02:21Z","timestamp":1657256541000},"page":"1424-1435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2349-3042","authenticated-orcid":false,"given":"Xiantong","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2340-6727","authenticated-orcid":false,"given":"Xianghai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-8371","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"5748_CR1","doi-asserted-by":"publisher","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","DOI":"10.1056\/NEJMoa1811744"},{"key":"5748_CR2","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","DOI":"10.1056\/NEJMoa1611925"},{"key":"5748_CR3","doi-asserted-by":"publisher","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","DOI":"10.1056\/NEJMoa1504720"},{"issue":"7","key":"5748_CR4","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2337\/dci20-0022","volume":"43","author":"WK Chung","year":"2020","unstructured":"Chung WK, Erion K, Florez JC et al (2020) Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 43(7):1617\u20131635. https:\/\/doi.org\/10.2337\/dci20-0022","journal-title":"Diabetes Care"},{"key":"5748_CR5","doi-asserted-by":"publisher","unstructured":"Ahlqvist E, Storm P, Karajamaki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361\u2013369. https:\/\/doi.org\/10.1016\/S2213-8587(18)30051-2","DOI":"10.1016\/S2213-8587(18)30051-2"},{"key":"5748_CR6","doi-asserted-by":"publisher","unstructured":"Zou X, Zhou X, Zhu Z, Ji L (2019) Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol 7(1):9\u201311. https:\/\/doi.org\/10.1016\/S2213-8587(18)30316-4","DOI":"10.1016\/S2213-8587(18)30316-4"},{"key":"5748_CR7","doi-asserted-by":"publisher","unstructured":"Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 7(6):442\u2013451. https:\/\/doi.org\/10.1016\/S2213-8587(19)30087-7","DOI":"10.1016\/S2213-8587(19)30087-7"},{"key":"5748_CR8","doi-asserted-by":"publisher","unstructured":"Ahlqvist E, Tuomi T, Groop L (2019) Clusters provide a better holistic view of type 2 diabetes than simple clinical features. Lancet Diabetes Endocrinol 7(9):668\u2013669. https:\/\/doi.org\/10.1016\/S2213-8587(19)30257-8","DOI":"10.1016\/S2213-8587(19)30257-8"},{"issue":"1","key":"5748_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41591-018-0239-8","volume":"25","author":"S Ravizza","year":"2019","unstructured":"Ravizza S, Huschto T, Adamov A et al (2019) Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data. Nat Med 25(1):57\u201359. https:\/\/doi.org\/10.1038\/s41591-018-0239-8","journal-title":"Nat Med"},{"key":"5748_CR10","doi-asserted-by":"publisher","unstructured":"Stenl\u00f6f K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4):372\u2013382. https:\/\/doi.org\/10.1111\/dom.12054","DOI":"10.1111\/dom.12054"},{"issue":"12","key":"5748_CR11","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez FJ, Januszewicz A, Davidson J et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56(12):2582\u20132592. https:\/\/doi.org\/10.1007\/s00125-013-3039-1","journal-title":"Diabetologia"},{"key":"5748_CR12","doi-asserted-by":"publisher","unstructured":"Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941\u2013950. https:\/\/doi.org\/10.1016\/s0140-6736(13)60683-2","DOI":"10.1016\/s0140-6736(13)60683-2"},{"issue":"12","key":"5748_CR13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","volume":"21","author":"JC Levy","year":"1998","unstructured":"Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21(12):2191\u20132192. https:\/\/doi.org\/10.2337\/diacare.21.12.2191","journal-title":"Diabetes Care"},{"key":"5748_CR14","unstructured":"European Medicines Agency (2012) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus-revision_en.pdf, accessed 5 April 2022"},{"key":"5748_CR15","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","DOI":"10.1056\/NEJMoa1812389"},{"key":"5748_CR16","doi-asserted-by":"publisher","unstructured":"Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7(9):684\u2013694. https:\/\/doi.org\/10.1016\/s2213-8587(19)30187-1","DOI":"10.1016\/s2213-8587(19)30187-1"},{"key":"5748_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.diabres.2018.06.008","volume":"143","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ (2018) Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 143:88\u2013100. https:\/\/doi.org\/10.1016\/j.diabres.2018.06.008","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"5748_CR18","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/jch.14397","volume":"23","author":"Z Khitan","year":"2021","unstructured":"Khitan Z, Nath T, Santhanam P (2021) Machine learning approach to predicting albuminuria in persons with type 2 diabetes: An analysis of the LOOK AHEAD Cohort. J Clin Hypertens (Greenwich) 23(12):2137\u20132145. https:\/\/doi.org\/10.1111\/jch.14397","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"5748_CR19","doi-asserted-by":"publisher","first-page":"11862","DOI":"10.1038\/s41598-019-48263-5","volume":"9","author":"M Makino","year":"2019","unstructured":"Makino M, Yoshimoto R, Ono M et al (2019) Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning. Scientific Reports 9(1):11862. https:\/\/doi.org\/10.1038\/s41598-019-48263-5","journal-title":"Scientific Reports"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05748-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-022-05748-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05748-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:02:50Z","timestamp":1688774570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-022-05748-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5748"],"URL":"https:\/\/doi.org\/10.1007\/s00125-022-05748-9","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"31 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}